statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

THRD's total volume now sits at 229.4K. The +-0.21% price change was insignificant, leaving IBM's price at $9.44...

The volume for Third Harmonic Bio stock increased for one day, resulting in a record-breaking daily growth of 204% of the 65-Day Volume Moving Average

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases...

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

Third Harmonic Bio, Inc. (THRD) has issued an update. Geoff McDonough has been appointed as a Class III director at Third Harmonic Bio, Inc., follo...

Third Harmonic Bio Welcomes New Director, Geoff McDonough

THRD's Fiscal Discipline Leads to Lower Annual Net Loss Despite Zero RevenueRelated Stocks: THRD...

Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN...

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

Third Harmonic Bio GAAP EPS of -$2.45 misses by $1.20...

Third Harmonic Bio GAAP EPS of -$2.45 misses by $1.20

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on THRD stock, giving a Buy rating today. Sam Slutsky has given his Buy rat...

Buy Rating for Third Harmonic Bio Amidst Promising Drug Pipeline and Market Potential

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Third Harmonic Bio, Inc. (THRD Research Report). The company's...

TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)

Recap: Third Harmonic Bio Q4 Earnings

THRD's total volume now sits at 574.6K. The +2.46% price change was insignificant, leaving IBM's price at $9.99...

The volume for Third Harmonic Bio stock increased for one day, resulting in a record-breaking daily growth of 291% of the 65-Day Volume Moving Average

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Watchers	116
52-Wk Low	$4.51
52-Wk High	$14.58

Volume	62,843.00
52-Wk High	$14.58
52-Wk Low	$4.51

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.32	--	--	N/A
Q1'24	-$0.31	$0.20	164.50%	BEAT
Q4'23	-$0.31	--	--	N/A
Q3'23	-$0.28	--	--	N/A
Q2'23	-$0.40	--	--	N/A

THRD THIRD HARMONIC BIO INC

About

Feed

News

Earnings

Fundamentals